-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

Benzinga·06/01/2026 11:03:07
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.